Skip to main content
SpringerLink
Log in

Neues aus der S3-Leitlinie Mammakarzinom

Von der Risikopatientin bis zur Nachsorge

  • CME Fortbildung
  • Published:
CME Aims and scope

Zusammenfassung

Mit ca. 69.000 jährlichen Neuerkrankungen in Deutschland ist das Mammakarzinom der häufigste maligne Tumor der Frau. Die Lebenszeitprävalenz liegt bei etwa 12%. Zu den wichtigsten Risikofaktoren zählen endokrine Faktoren, Lebensalter und Prädisposition. Tastbefunde oder Hautveränderungen zeigen sich meist erst im fortgeschrittenen Stadium, deshalb beinhaltet die Früherkennung neben der klinischen Untersuchung eine Mammografie (standardmäßig ab 50 Jahren). Bei auffälligem Befund erfolgt eine histologische Abklärung. Mit der Diagnosestellung eines Mammakarzinoms folgen in definierten Situationen zum Ausschluss einer Fernmetastasierung die Staginguntersuchungen. Die Operation ist ein wichtiger Teilschritt der kurativen Therapie. Zusätzlich sollte die Behandlung eine Strahlentherapie (bei brusterhaltender OP, positivem Lymphknotenstatus etc.) sowie abhängig von der Tumorbiologie und dem individuellen Patientenrisiko eine Systemtherapie (Chemo-, Antikörper-, Antihormontherapie) beinhalten. Aufgrund der Heterogenität der Tumorbiologie ergibt sich eine individuell auf die Patientin ausgerichtete Therapie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. The Lancet Oncology. 2012;13(11):1141-51.

  2. Ellis IO. Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2010;23 Suppl 2:S1–7.

    Article  CAS  Google Scholar 

  3. Nunez C, Bauman A, Egger S, Sitas F, Nair-Shalliker V. Obesity, physical activity and cancer risks: Results from the Cancer, Lifestyle and Evaluation of Risk Study (CLEAR). Cancer epidemiology. 2017;47:56–63.

    Article  Google Scholar 

  4. Rodgers KM, Udesky JO, Rudel RA, Brody JG. Environmental chemicals and breast cancer: An updated review of epidemiological literature informed by biological mechanisms. Environ Res. 2018;160:152–82.

    Article  CAS  Google Scholar 

  5. Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC cancer. 2018;18(1):265.

    Article  Google Scholar 

  6. Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marme F, et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PloS one. 2017;12(10):e0186043.

    Article  Google Scholar 

  7. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Jama. 2017;317(23):2402–16.

    Article  CAS  Google Scholar 

  8. De Felice F, Marchetti C, Musella A, Palaia I, Perniola G, Musio D, et al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Annals of surgical oncology. 2015;22(9):2876–80.

    Article  Google Scholar 

  9. Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. The Lancet Oncology. 2006;7(3):223–9.

    Article  CAS  Google Scholar 

  10. Broeders M, Moss S, Nystrom L, Njor S, Jonsson H, Paap E, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. Journal of medical screening. 2012;19 Suppl 1:14–25.

    Article  Google Scholar 

  11. Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, et al. Benefits and Harms of Breast Cancer Screening: A Systematic Review. Jama. 2015;314(15):1615–34.

    Article  CAS  Google Scholar 

  12. Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. The Lancet Oncology. 2015;16(9):1123–32.

    Article  Google Scholar 

  13. Schaefer FK, Waldmann A, Katalinic A, Wefelnberg C, Heller M, Jonat W, et al. Influence of additional breast ultrasound on cancer detection in a cohort study for quality assurance in breast diagnosis-analysis of 102,577 diagnostic procedures. European radiology. 2010;20(5):1085–92.

    Article  Google Scholar 

  14. Melnikow J, Fenton JJ, Whitlock EP, Miglioretti DL, Weyrich MS, Thompson JH, et al. Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force. Annals of internal medicine. 2016;164(4):268–78.

    Article  Google Scholar 

  15. Ohuchi N, Suzuki A, Sobue T, Kawai M, Yamamoto S, Zheng YF, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet (London, England). 2016;387(10016):341–8.

    Article  Google Scholar 

  16. Mueller-Schimpfle MP, Brandenbusch VC, Degenhardt F, Duda V, Madjar H, Mundinger A, et al. The Problem of Mammographic Breast Density - The Position of the DEGUM Working Group on Breast Ultrasound. Ultraschall in der Medizin (Stuttgart, Germany: 1980). 2016;37(2):170–5.

    Article  CAS  Google Scholar 

  17. National Collaborating Centre for C. National Institute for Health and Clinical Excellence: Guidance. Advanced Breast Cancer: Diagnosis and Treatment. Cardiff (UK): National Collaborating Centre for Cancer (UK) National Collaborating Centre for Cancer.; 2009.

  18. Bennani-Baiti B, Bennani-Baiti N, Baltzer PA. Diagnostic Performance of Breast Magnetic Resonance Imaging in Non-Calcified Equivocal Breast Findings: Results from a Systematic Review and Meta-Analysis. PloS one. 2016;11(8):e0160346.

    Article  Google Scholar 

  19. http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/. 10.06.2019; 4.1 September 2018.

  20. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.

    Article  Google Scholar 

  21. O'Higgins N, Linos DA, Blichert-Toft M, Cataliotti L, de Wolf C, Rochard F, et al. European guidelines for quality assurance in the surgical management of mammographically detected lesions. European Breast Cancer Working Group. Annales chirurgiae et gynaecologiae. 1998;87(1):110–2.

    CAS  PubMed  Google Scholar 

  22. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. Jama. 2017;318(10):918–26.

    Article  Google Scholar 

  23. Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016;375(8):717–29.

    Article  CAS  Google Scholar 

  24. Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, et al. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). Journal of the National Cancer Institute Monographs. 2015;2015(51):90–6.

    Article  Google Scholar 

  25. van Hellemond IEG, Geurts SME, Tjan-Heijnen VCG. Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. Current treatment options in oncology. 2018;19(5):26.

    Article  Google Scholar 

  26. Burstein HJ, Lacchetti C, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of oncology practice. 2019;15(2):106–7.

    Article  Google Scholar 

  27. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018;379(2):122–37.

    Article  CAS  Google Scholar 

  28. Silverstein MJ, Fastner G, Maluta S, Reitsamer R, Goer DA, Vicini F, et al. Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials. Part 2—TARGIT. Annals of surgical oncology. 2014;21(12):3793–9.

    Article  Google Scholar 

  29. Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(31):5091–7.

    Article  Google Scholar 

  30. Muuller RD, Barkhausen J, Sauerwein W, Langer R. Assessment of local recurrence after breast-conserving therapy with MRI. Journal of computer assisted tomography. 1998;22(3):408–12.

    Article  CAS  Google Scholar 

  31. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003;21(21):4042–57.

    Article  CAS  Google Scholar 

  32. www.ago-online.de. 28.07.2019.

  33. Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Annals of oncology: official journal of the European Society for Medical Oncology. 2014;25(10):1901–14.

    Article  CAS  Google Scholar 

  34. https://www.tumorregister-muenchen.de/facts/spec/spec_C50f__20_20170629_OutmodSubtypPoster.pdf. 22.08.2019.

  35. Giersiepen K, Heitmann C, Janhsen K, Lange C. Brustkrebs. Gesundheitsberichterstattung des Bundes - Themenhefte. 2005;25.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Frauenklinik und Poliklinik, Universität Würzburg, Josef-Schneider-Str. 4, 97080, Würzburg, Deutschland

    Saskia-Laureen Herbert,  Tanja Stüber,  Joachim Diessner &  Achim Wöckel

Authors
  1. Saskia-Laureen Herbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tanja Stüber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joachim Diessner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Achim Wöckel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saskia-Laureen Herbert.

Additional information

Interessenkonflikt

Prof. Wöckel gibt Honorare für Beratungen und Vorträge sowie die Unterstützung von Fachfortbildungen von Amgen, Novartis, Eisai, Celgene, Pfizer, Tesaro, Aurikamed, TEVA, Lilly, Roche, Astra Zeneca, Sirtex, MSD, Genomic Health innerhalb der letzten fünf Jahre an. Dr. Stüber gibt an, Honorare von Roche, Pfizer und Celgene erhalten zu haben. PD Dr. Diessner gibt Honorare von Roche, Novartis, Tesaro, Astra Zeneca, Amgen, Lilly und MSD an.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Herbert, SL., Stüber, T., Diessner, J. et al. Neues aus der S3-Leitlinie Mammakarzinom. CME 16, 51–62 (2019). https://doi.org/10.1007/s11298-019-7098-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11298-019-7098-6

Schlüsselwörter

Search

Navigation